These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18691304)

  • 21. Physician and patient survey of allergic rhinitis: methodology.
    Higgins V; Kay S; Small M
    Allergy; 2007; 62 Suppl 85():6-8. PubMed ID: 17927672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life analysis of patients undergoing immunotherapy for allergic rhinitis.
    Fell WR; Mabry RL; Mabry CS
    Ear Nose Throat J; 1997 Aug; 76(8):528-32, 534-6. PubMed ID: 9282460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allergic rhinitis management pocket reference 2008.
    Bousquet J; Reid J; van Weel C; Baena Cagnani C; Canonica GW; Demoly P; Denburg J; Fokkens WJ; Grouse L; Mullol K; Ohta K; Schermer T; Valovirta E; Zhong N; Zuberbier T
    Allergy; 2008 Aug; 63(8):990-6. PubMed ID: 18691301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of patient care provider on patient health outcomes in allergic rhinitis.
    Szeinbach SL; Williams PB; Kucukarslan S; Elhefni H
    Ann Allergy Asthma Immunol; 2005 Aug; 95(2):167-74. PubMed ID: 16136767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome measures of specific immunotherapy.
    Pfaar O; Anders C; Klimek L
    Curr Opin Allergy Clin Immunol; 2009 Jun; 9(3):208-13. PubMed ID: 19365259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with allergic rhinitis in Priest Hospital.
    Pratyapipat S; Sinsakolwat J; Tantanawat A
    J Med Assoc Thai; 2008; 91 Suppl 1():S68-72. PubMed ID: 18672596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is reliance on self-medication and pharmacy care adequate for rhinitis patients?
    Williams A; Scadding G
    Int J Clin Pract; 2009 Jan; 63(1):98-104. PubMed ID: 19125997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term allergen-specific immunotherapy correlates with long-term allergen-specific immunological tolerance.
    Ali I; Goksal K; Ozan B; Gulsen D
    Adv Ther; 2008 Jan; 25(1):29-36. PubMed ID: 18224290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single center study of clinical and paraclinical aspects in Iranian patients with allergic rhinitis.
    Mohammadi K; Gharagozlou M; Movahedi M
    Iran J Allergy Asthma Immunol; 2008 Sep; 7(3):163-7. PubMed ID: 18780951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Congruence between international guidelines and mite specific immunotherapy prescribing practices.
    Antonicelli L; Braschi MC; Bilò MB; Angino A; Pala AP; Baldacci S; Maio S; Bonifazi F
    Respir Med; 2011 Oct; 105(10):1441-8. PubMed ID: 21628094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility weights for allergic rhinitis based on a community survey with a time trade-off technique in Japan.
    Tamayama K; Kondo M; Shono A; Okubo I
    Allergol Int; 2009 Jun; 58(2):201-7. PubMed ID: 19240376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis.
    Bousquet PJ; Combescure C; Klossek JM; Daurès JP; Bousquet J
    J Allergy Clin Immunol; 2009 Jun; 123(6):1349-54. PubMed ID: 19368963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis.
    Okano M; Otsuki N; Azuma M; Fujiwara T; Kariya S; Sugata Y; Higaki T; Kino K; Tanimoto Y; Okubo K; Nishizaki K
    Clin Exp Allergy; 2008 Dec; 38(12):1891-900. PubMed ID: 19016801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX) in a randomized, open-label, controlled study: an a priori subgroup analysis.
    Jansen A; Andersen KF; Brüning H
    Clin Ther; 2009 Feb; 31(2):321-7. PubMed ID: 19302904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of allergic reactivity and disease in Olympic athletes.
    Katelaris CH; Carrozzi FM; Burke TV; Byth K
    Clin J Sport Med; 2006 Sep; 16(5):401-5. PubMed ID: 17016116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical validity of our new patient satisfaction questionnaire for allergic rhinitis].
    Okuda M; Ohkubo K; Gotoh M
    Arerugi; 2005 Jan; 54(1):12-7. PubMed ID: 15841671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of allergic rhinitis in clinical practice and its pharmacoeconomic aspects].
    Gazdík F; Gajdosová K; Springer V; Gazdíková K
    Ceska Slov Farm; 2002 Jul; 51(4):190-5. PubMed ID: 12183907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The results of specific immunotherapy for house dust mites in patients with allergic rhinitis].
    Sahin E; Taş E; Dağtekin Ergür EN; Cuhali BD; Gürsel AO
    Kulak Burun Bogaz Ihtis Derg; 2008; 18(2):79-84. PubMed ID: 18628641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific immunotherapy for allergic rhinitis in Italy: the doctors points of view.
    Larosa M; Ciprandi G; Tesi CF; Cadario G; Fiocchi A; Frati F; Romano A
    Int J Immunopathol Pharmacol; 2009; 22(1):251-154. PubMed ID: 19309575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.